Medacta commenced U.S. launch of the MiniMAX™ anatomical cementless hip stem, suitable for minimally invasive anterior and posterior procedures.
The MiniMAX stem was launched in 2007 in Europe, and company research indicates a 97.5% survival rate at 5 years following revision and a 100% survival rate with aseptic loosening as a study endpoint.
Medacta commenced U.S. launch of the MiniMAX™ anatomical cementless hip stem, suitable for minimally invasive anterior and posterior procedures.
The MiniMAX stem was launched in 2007 in Europe, and company research indicates a 97.5% survival rate at 5 years following revision and a 100% survival rate with aseptic loosening as a study...
Medacta commenced U.S. launch of the MiniMAX™ anatomical cementless hip stem, suitable for minimally invasive anterior and posterior procedures.
The MiniMAX stem was launched in 2007 in Europe, and company research indicates a 97.5% survival rate at 5 years following revision and a 100% survival rate with aseptic loosening as a study endpoint.
Copy to clipboard 
